ArticleCancer immunology, immunotherapy : CII2022
CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1
Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- CX3CR1⁺ CD8⁺ cytotoxic T cells drive tumor killing in esophageal squamous cell carcinoma during neoadjuvant therapy.Nature communications · 2026Article
- Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy.Nature communications · 2026Article
- mRNA vaccines for hepatocellular carcinoma: mechanisms, therapeutic strategies, and clinical perspectives.Hepatology international · 2026Review
- CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting.Cancers · 2026Review
- Synergistic activation of dendritic cells by Lycium barbarum polysaccharide and tumor endothelial progenitor cell lysate enhances anti-tumor responses.Scientific reports · 2026Article
- Potential CD27-CD70 interaction within adoptive T cells does not affect tumor antigen-specific T-cell immunotherapy.ImmunoHorizons · 2026Article
- Multimodal tumor thermal therapy enhances antitumor immunity by expanding tumor-reactive CX3CR1⁺GPR56⁺ T cells in hepatocellular carcinoma.Theranostics · 2026Article
- Dendritic cells in cancer immunotherapy: functional barriers, reprogramming strategies and translational challenges.Frontiers in immunology · 2026Review
- Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation.Molecular therapy. Oncology · 2025Article
- Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma.Journal for immunotherapy of cancer · 2025Article
- CX3CR1Cancer science · 2024Review
- Expansion of tumor-reactive CD8Science immunology · 2024Article
- CD27 signaling inhibits tumor growth and metastasis via CD8 + T cell-independent mechanisms in the B16-F10 melanoma model.Cancer immunology, immunotherapy : CII · 2024Article
- Generation, Transcriptomic States, and Clinical Relevance of CX3CR1+ CD8 T Cells in Melanoma.Cancer research communications · 2024Article
- Dendritic cells as orchestrators of anticancer immunity and immunotherapy.Nature reviews. Clinical oncology · 2024Review
- Dendritic cell subsets and implications for cancer immunotherapy.Frontiers in immunology · 2024Review
- Predictive and Prognostic Implications of Circulating CX3CR1Cancer research communications · 2023Article
- Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies.Vaccines · 2022Review
- Engineering neoantigen vaccines to improve cancer personalized immunotherapy.International journal of biological sciences · 2022Review
- Know thy immune self and non-self: Proteomics informs on the expanse of self and non-self, and how and where they arise.Proteomics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The use of tumor mutation-derived neoantigen represents a promising approach for cancer vaccines. Preclinical and early phase human clinical studies have shown the successful induction of tumor neoepitope-directed responses; however, overall clinical efficacy of neoantigen vaccines has been limited. One major obstacle of this strategy is the prevailing lack of sufficient understanding of the mechanism underlying the generation of neoantigen-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.